These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26332059)

  • 21. Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience.
    Kondo T; Ikezawa E; Takagi T; Kobayashi H; Hashimoto Y; Iizuka J; Omae K; Yoshida K; Tanabe K
    Int J Urol; 2013 Nov; 20(11):1072-7. PubMed ID: 23421632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncological outcomes of hand-assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single-institution study with >or=3 years of follow-up.
    Bandi G; Christian MW; Hedican SP; Moon TD; Nakada SY
    BJU Int; 2008 Feb; 101(4):459-62. PubMed ID: 17941924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal cell carcinoma invading the urinary collecting system: implications for staging.
    Uzzo RG; Cherullo E; Myles J; Novick AC
    J Urol; 2002 Jun; 167(6):2392-6. PubMed ID: 11992044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.
    Klatte T; Patard JJ; Wunderlich H; Goel RH; Lam JS; Junker K; Schubert J; Böhm M; Allhoff EP; Kabbinavar FF; Crepel M; Cindolo L; De La Taille A; Tostain J; Mejean A; Soulie M; Bellec L; Bernhard JC; Ferriere JM; Pfister C; Albouy B; Colombel M; Zisman A; Belldegrun AS; Pantuck AJ
    J Urol; 2007 Jun; 177(6):2081-6; discussion 2086-7. PubMed ID: 17509291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma?
    Méjean A; Rouprêt M; Larousserie F; Hopirtean V; Thiounn N; Dufour B
    J Urol; 2003 Apr; 169(4):1287-90. PubMed ID: 12629344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localized non-conventional renal cell carcinoma: prediction of clinical outcome according to histology.
    Kim SH; Yang HK; Moon KC; Lee ES
    Int J Urol; 2014 Apr; 21(4):359-64. PubMed ID: 24224568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base.
    Nese N; Paner GP; Mallin K; Ritchey J; Stewart A; Amin MB
    Ann Diagn Pathol; 2009 Feb; 13(1):1-8. PubMed ID: 19118775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
    May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
    J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laparoscopic partial nephrectomy: evaluation of long-term oncological outcome.
    Allaf ME; Bhayani SB; Rogers C; Varkarakis I; Link RE; Inagaki T; Jarrett TW; Kavoussi LR
    J Urol; 2004 Sep; 172(3):871-3. PubMed ID: 15310986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma.
    Gayed BA; Youssef RF; Bagrodia A; Darwish OM; Kapur P; Sagalowsky A; Lotan Y; Margulis V
    BJU Int; 2014 Apr; 113(4):668-73. PubMed ID: 23937277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
    Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
    Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term results in the treatment of 100 metastatic hypernephroid carcinomas].
    Falk W; Halama JM; Halama J
    Strahlenther Onkol; 1990 Apr; 166(4):256-64. PubMed ID: 2139518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
    Leibovich BC; Lohse CM; Crispen PL; Boorjian SA; Thompson RH; Blute ML; Cheville JC
    J Urol; 2010 Apr; 183(4):1309-15. PubMed ID: 20171681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.